Percutaneous dilational tracheostomy in patients receiving antiplatelet therapy: is it safe?

Area of Science:

• Cardiology
• Pulmonology
• Surgical Procedures

Background:

• Antiplatelet agents are crucial for vascular diseases but increase bleeding risk.
• Bleeding complications can compromise the safety of invasive procedures.
• Percutaneous dilational tracheostomy (PDT) is an invasive procedure requiring careful risk assessment.

Purpose of the Study:

• To evaluate the bleeding risk associated with percutaneous dilational tracheostomy (PDT) in patients taking antiplatelet therapy.
• To compare bleeding rates between patients on clopidogrel and a control group undergoing PDT.

Main Methods:

• Retrospective chart review of patients undergoing PDT across two institutions.
• Inclusion of a study group receiving clopidogrel and a control group.
• Analysis of bleeding complications (major and minor) post-PDT.

Main Results:

• No major bleeding events were reported in either the clopidogrel group or the control group.
• Minor bleeding occurred in 5% of the clopidogrel group versus 3.6% in the control group (P=0.85).
• The incidence of bleeding was not significantly different between the groups.

Conclusions:

• Percutaneous dilational tracheostomy (PDT) can be safely performed without discontinuing clopidogrel.
• Continuation of antiplatelet therapy is supported when there is a clear indication.
• This finding enhances procedural safety for patients requiring both PDT and antiplatelet medication.